SCHEMBL7941319

SCHEMBL7941319

O=C(O)c1cc(I)c(O)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.41
KDM4E B2RXH2 6/20 0.41
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
ALB P02768 2/20 0.39
ACMSD Q8TDX5 2/20 0.39
TP53 P04637 2/20 0.39
AKR1C2 P52895 2/20 0.38
AKR1C1 Q04828 2/20 0.38
CA1 P00915 6/20 0.38
CA2 P00918 6/20 0.38
ALDH1A1 P00352 6/20 0.38
CA12 O43570 4/20 0.38
CA7 P43166 4/20 0.38
CA9 Q16790 4/20 0.38
CA14 Q9ULX7 4/20 0.38
HPGD P15428 4/20 0.38
HSD17B10 Q99714 3/20 0.38
LMNA P02545 2/20 0.38
HMGB1 P09429 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15877748 0.92 TTR (0.41) TTRKDM4EASPHKDM8ALB
SCHEMBL1045113 0.83 KDM4E (0.44) TTRKDM4EASPHKDM8ALB
SCHEMBL22222257 0.82 KDM4E (0.47) TTRKDM4EASPHKDM8ALB
SCHEMBL30892458 0.82 KDM4E (0.47) TTRKDM4EASPHKDM8ALB
Hydrochloric Acid SCHEMBL17536154 0.81 KDM4E (0.42) TTRKDM4EASPHKDM8ALB
SCHEMBL4367594 0.80 KDM4E (0.45) TTRKDM4EASPHKDM8ALB
SCHEMBL15829176 0.80 CA1 (0.46) KDM4EACMSDTP53CA1CA2
SCHEMBL18713921 0.78 KEAP1 (0.44) TTRKDM4EASPHKDM8ALB
SCHEMBL17880615 0.78 KDM4E (0.40) TTRKDM4EASPHKDM8ALB
SCHEMBL31356642 0.78 KDM4E (0.40) TTRKDM4EASPHKDM8ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed
WO-2010054278-A2 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 TTR 802/4885KDM4E 4592/4885ASPH 117/4885
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 TTR 2617/4885KDM4E 420/4885ASPH 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.